Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival.

Catherine Zabkiewicz,Jeyna Resaul,Rachel Hargest,Wen Guo Jiang,Lin Ye
DOI: https://doi.org/10.21873/cgp.20035
2017-01-01
Cancer Genomics & Proteomics
Abstract:BACKGROUND/AIM Activin and its antagonist follistatin (FST) have been implicated in several solid tumours. This study investigated the role of FST in breast cancer. MATERIALS AND METHODS FST expression was examined using reverse transcription polymerase chain reaction (RT-PCR), real-time quantitative polymerase chain reaction (qPCR) and immunohistochemistry in a cohort of breast cancer samples. Expression was correlated to pathological and prognostic parameters in our patient cohort. FST was overexpressed in MCF-7 cells and assays for growth and invasion were performed. RESULTS FST is expressed in breast tissue, in the cytoplasm of mammary epithelial cells. Expression was decreased in breast cancer tissue in comparison to normal mammary tissue. Over-expression of FST in vitro led to significantly increased growth rate and reduced invasion. Higher FST associates with lower-grade tumours and better survival. CONCLUSION Our results suggest a role for FST as a suppressor of invasion and metastasis in breast cancer.
What problem does this paper attempt to address?